3Q 2025 Earnings Conference Call

November 5, 2025

CORTEVA™ agriscience

Safe Harbor Regarding Forward-Looking Statements

Forward-Looking Statements

This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates,” “outlook,” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; sustainability targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva’s business, results of operations and financial condition. Some of the important factors that could cause Corteva’s actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of Corteva’s products; (ii) failure to successfully develop and commercialize Corteva’s pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vi) effect of climate change and unpredictable seasonal and weather factors; (vii) failure to comply with competition and antitrust laws; (viii) effect of competition in Corteva's industry; (ix) competitor’s establishment of an intermediary platform for distribution of Corteva's products; (x) risks related to recent funding and staff reductions at U.S. government agencies; (xi) risk related to geopolitical and military conflict; (xii) effect of volatility in Corteva's input costs; (xiii) risks related to Corteva's global operations; (xiv) effect of industrial espionage and other disruptions to Corteva’s supply chain, information technology or network systems; (xv) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the Corteva Separation; (xvi) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xvii) failure of Corteva’s customers to pay their debts to Corteva, including customer financing programs; (xviii) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xix) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xx) increases in pension and other post-employment benefit plan funding obligations; (xxi) risks related to pandemics or epidemics; (xxii) capital markets sentiment towards sustainability matters; (xxiii) Corteva’s intellectual property rights or defense against intellectual property claims asserted by others; (xxiv) effect of counterfeit products; (xxv) Corteva’s dependence on intellectual property cross-license agreements; (xxvi) risks related to Corteva’s Separation from DowDuPont; and (xxvii) risks related to Corteva’s proposed separation, including, but not limited to, whether the objectives of the proposed separation will be achieved; the terms, structure, benefits and costs of any action or transaction resulting from the proposed separation; the timing of any such separation or related action and whether any such separation will be consummated at all; the risk the proposed separation could divert the attention and time of the company’s management; the risk of any unexpected costs or expenses resulting from the proposed separation process or separation itself; and the risk of any litigation as a result of, or relating to, the proposed separation.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled “Risk Factors” in Corteva’s annual and quarterly reports filed on Forms 10-K and 10-Q with the U.S. Securities and Exchange Commission.

Safe Harbor Regarding Forward-Looking Statements

Regulation G (Non-GAAP Financial Measures)

This presentation includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include organic sales, organic growth (including by segment and region), operating EBITDA, operating EBITDA margin, operating earnings (loss) per share, and base income tax rate. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results.

These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided at the end of this presentation.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures, except for Free Cash Flow, to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, such as Significant Items, without unreasonable effort. For Significant items reported in the periods presented, refer to slide 32. Beginning January 1, 2020, the Company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the non-cash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. Due to the ramp-up of Enlist E3™, Corteva significantly reduced the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform thereafter. In 2023 and 2024, the company committed to restructuring activities to optimize the Crop Protection network of manufacturing and external partners, which are expected to be substantially complete in 2026. The company expects to record approximately $160 million to $175 million net pre-tax restructuring charges during 2025 for these activities.

Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items. Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense. Operating EBITDA margin is defined as Operating EBITDA as a percentage of net sales. Operating earnings (loss) per share is defined as "earnings (loss) per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of separation costs, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Corteva Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the Company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility. Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), significant items, separation costs, amortization of intangibles (existing as of Corteva Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and non-operating (benefits) costs.

The Company also uses Free Cash Flow and Free Cash Flow Conversion as non-GAAP measures to evaluate and discuss its liquidity position and ability to generate cash. Free Cash Flow is defined as cash provided by (used for) operating activities – continuing operations, less capital expenditures. Free Cash Flow Conversion is defined as Free Cash Flow divided by Operating EBITDA. We believe that Free Cash Flow and Free Cash Flow Conversion provide investors with meaningful information regarding the Company's ongoing ability to generate cash through core operations, and our ability to service our indebtedness, pay dividends (when declared), make share repurchases, and meet our ongoing cash needs for our operations. Corteva is not able to reconcile its forward-looking Free Cash Flow Conversion non-GAAP financial measure to its most comparable U.S. GAAP financial measure, as it is unable to predict with reasonable certainty Operating EBITDA due to items outside of the company's control, which includes the same Significant Items noted above, without unreasonable effort.

On Track to Separate into Two Market-Leading Public Companies

New Corteva

Driven by technology and innovation, delivering differentiated solutions in crop protection and plant health, backed by operational excellence and a comprehensive global portfolio with attractive growth platforms in natural products including biologicals

SpinCo

An unrivaled innovator in advanced genetics with a century-long track record poised to accelerate growth through emerging technologies including gene editing, hybrid wheat, and biofuels with broad-based application of artificial intelligence

Dedicated Separation Management Team have Key Planning In-Progress:

- Board / key leadership selection
- Capital structure design
- Corporate governance framework
- IT systems stand-up
- Form 10 preparation
- SpinCo name and branding

Two Compelling Investment Opportunities; Set to Close in 2H 2026

CEO Messages

Strong YTD Financial Performance

- Growth platforms and operational excellence accelerating margin improvement
- Seed results reflect growing demand for newest hybrids and varieties
- Crop Protection new products and biologicals delivering double-digit volume growth

Overall Ag Market Outlook

- Record consumption of grain, oilseeds, feed, and biofuels continues in 2025
- On-farm demand strong as farmers prioritize premium crop input technologies
- Uncertainty remains on global trade policy; farmer margins pressured

Raising FY 2025 Outlook(2)

- Operating EBITDA(1) $3.80 – $3.90B, 14% growth vPY at mid-point
- ~165 bps of Operating EBITDA margin(1) improvement vPY
- On track for ~$1B in share repurchases for FY 2025

YTD Earnings Surpass FY24 | FY26 Prelim View Shows MSD Growth

(1) Operating EBITDA and Operating EBITDA Margin are non-GAAP measures. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) Guidance does not contemplate any extreme weather events, operational disruptions, significant changes in customers' demand or ability to pay, further acceleration of currency and inflation impacts resulting from macro-economic driven trends, changes in global tariff policy, any escalation of military conflict, or any material change in the socio-political environment.

Preliminary View on 2026

Market Backdrop	Corteva Expectations
▪ Strong global consumption of grains and oilseeds	▪ Seed gains driven by new hybrids and varieties
▪ On-farm product demand continues to grow	▪ CP New Product / Biologicals volume gains
▪ LSD organic growth in Crop Protection industry	▪ Ongoing productivity and cost benefits
▪ Logical shift in U.S. planted area from corn to soy	▪ Manageable level of separation dis-synergies
▪ Farmers prioritize seed selection while managing tight margins and global trade uncertainty	▪ Continued growth in R&D investment
	▪ Currency tailwind from stronger BRL

$4.1B Full-Year Operating EBITDA at the Mid-Point

Strong Execution to Drive EBITDA Growth and Margin Expansion

2025 YTD Financial Performance

Metric	3Q 2025[1]	YTD 2025[1]	Highlights
Net Sales	**$2.6B** +13%	**$13.5B** +4%	Seed volume gains led by NA[3] and LA on strength of portfolio Crop Protection volume from new products, biologicals
Organic Sales[2]	**$2.6B** +11%	**$13.7B** +6%	Seed price/mix gains on strong NA corn demand Crop Protection organic sales growth in NA, LATAM, and EMEA
Operating EBITDA[2]	**$49M** +149%	**$3.4B** +19%	Seed productivity and lower input costs offset currency Crop Protection productivity and lower input costs offset currency
Operating EBITDA Margin[2]	**1.9%** n/m[4]	**25.2%** +317 bps	Seed margin expansion on price/mix, and productivity Crop Protection cost savings and volume driving margin expansion

Execution Across both Seed and CP Driving Margin Growth

CORTEVA™ agriscience

(1) Growth rates versus prior year.
(2) Organic sales, Operating EBITDA and Operating EBITDA Margin are non-GAAP measures. See slide 3 for further discussion and reconciliations at the end of this presentation.
(3) North America (NA) is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa.
(4) Not meaningful.

2025 YTD Operating EBITDA[1]

2025 YTD Bridge



Key Drivers

- **Seed price/mix gains** across the portfolio to capture value for technology, offset by Crop Protection competitive price pressures
- Favorable weather and strong portfolio enable **North America[2] Seed volume growth, early start to safrinha deliveries in Brazil**
- **Double-digit volume growth** in Crop Protection new products and biologicals
- **~$90M benefit from Seed net royalties**, driven by increased corn out-licensing income and lower soybean royalty expense
- **~$500M in productivity savings and lower input costs** across both Seed and Crop Protection
- Currency headwind primarily driven by **Brazilian Real**, **Turkish Lira** and **Canadian Dollar**

Strong YTD Operational Execution Driving Updated FY Guidance

(1) Operating EBITDA and Operating EBITDA margin are non-GAAP measures. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa.

Raising FY 2025 Guidance[1] Key Metrics

	Operating EBITDA[2]	Operating EBITDA Margin[2]	Operating EPS[2]	Free Cash Flow / EBITDA Conversion[2]
Revised Guidance	**$3.80 – $3.90B** +14% at mid-point	**~165 bps** Improvement	**$3.25 – $3.35** +28% at mid-point	**~50%**
Prior Guidance	$3.75 – $3.85B +13% at mid-point	~150 bps improvement	$3.00 – $3.20 +21% at mid-point	~50%
Key Drivers	Broad-based organic sales growth and increased benefit from cost improvements	Mid-single-digit net sales growth vs prior year	Increased Operating EBITDA growth and lower than expected net interest expense, EGL	Earnings growth and lower cash taxes

Expecting ~17% Operating EBITDA Growth in 2H

(1) Guidance does not contemplate any extreme weather events, operational disruptions, significant changes in customers' demand or ability to pay, further acceleration of currency and inflation impacts resulting from macro-economic driven trends, changes in global tariff policy, any escalation of military conflict, or any material change in the socio-political environment.
(2) Operating EBITDA, Operating EBITDA Margin, Operating EPS, Free Cash Flow, and Free Cash Flow Conversion are non-GAAP measures. Corteva is not able to reconcile its forward-looking non-GAAP financial measures, except Free Cash Flow, to their most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the company's control, such as Significant Items, without unreasonable effort. See slide 3 for further discussion.

Key Takeaways

Strong YTD 2025 Performance, Organic Growth in Crop Protection and Seed

Raising FY 2025 Sales, Earnings, and EPS Guidance

On-track to return ~$1.5B to Shareholders for FY 2025

Preliminary 2026 View reflects Sales, Operating EBITDA, and Margin Growth

Demand for Differentiated Technology and Operational Execution Driving Growth

Appendix

CORTEVA™ agriscience

3Q 2025 Highlights

($ in millions, except EPS)	3Q 2024	3Q 2025	Change
Net Sales	$2,326	$2,618	13%
GAAP Income (Loss) from Continuing Operations After Income Taxes	($519)	($308)	41%
Operating EBITDA[1]	($100)	$49	149%
Operating EBITDA Margin[1]	(4.3)%	1.9%	+617 bps
GAAP EPS from Continuing Operations	($0.76)	($0.46)	39%
Operating EPS[1]	($0.49)	($0.23)	53%

3Q 2025 Net Sales ($ in millions)



3Q 2025 Operating EBITDA [1] ($ in millions)



(1) Organic sales growth, Operating EBITDA, Operating EBITDA margin and Operating earnings per share are non-GAAP measures. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) North America is defined as U.S. and Canada. EMEA Is defined as Europe, Middle East and Africa.

3Q 2025 Seed Performance Highlights

($ in millions)	3Q 2025	vPY
Net Sales	$917	+33%
Organic[1] Sales Growth		+31%
Operating EBITDA	($193)	+40%
Operating EBITDA Margin	(21.0%)	n/m[3]

Seed Operating EBITDA ($ in millions)



3Q 2025 Revenue by Product Line



Summary Takeaways

- Price/mix gains in most regions on demand for technology, coupled with increased out-licensing income
- Higher corn volumes in LA on early safrinha deliveries
- Cost benefit from productivity and lower commodity costs partially offset by higher compensation, commissions, and R&D

CORTEVA agriscience

(1) Organic sales growth is a non-GAAP measure. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) Other oilseeds includes sunflower and canola.
(3) Not meaningful

(3) Other product line primarily includes cotton, alfalfa, sorghum, wheat, rice, inoculants, and millet.

3Q 2025 Regional Net Sales Highlights – Seed

Global Net Sales



Reported ↑ 33%

Organic[1] ↑ 31%

Volume	Price/Mix	Currency	Portfolio
27%	4%	2%	-%

North America[2]

Reported ↑ 3% | Organic[1] ↑ 4%

	3Q 2024	3Q 2025
Net Sales ($M)	$170	$175

Volume	Price/Mix	Currency	Portfolio
(8)%	12%	(1)%	-%

- Volume declines driven by higher cotton returns due to lower planted area
- Price/mix gains driven by increased out-licensing income

Latin America

Reported ↑ 79% | Organic[1] ↑ 76%

	3Q 2024	3Q 2025
Net Sales ($M)	$218	$391

Volume	Price/Mix	Currency	Portfolio
78%	(2)%	3%	-%

- Volume gains driven by early safrinha deliveries in Brazil and recovery of corn area in Argentina
- Price/mix declines driven by competitive corn technology alternatives in Argentina

EMEA[2]

Reported ↑ 34% | Organic[1] ↑ 31%

	3Q 2024	3Q 2025
Net Sales ($M)	$196	$262

Volume	Price/Mix	Currency	Portfolio
26%	5%	3%	-%

- Volume gains driven by strong demand for corn
- Price/mix gains driven by demand for technology

Asia Pacific

Reported ↓ 17% | Organic[1] ↓ 16%

	3Q 2024	3Q 2025
Net Sales ($M)	$107	$89

Volume	Price/Mix	Currency	Portfolio
(20)%	4%	(1)%	-%

- Volume declines due to delayed mustard season from heavy rains, pushing sales to 4Q, and early rice sales moving volumes to 2Q
- Strong price/mix execution across the portfolio

CORTEVA™ agriscience

(1) Organic sales growth is a non-GAAP measure. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) North America is defined as U.S. and Canada. EMEA Is defined as Europe, Middle East and Africa.

2025 YTD Seed Performance Highlights

($ in millions)	2025 YTD	vPY
Net Sales	$8,161	+5%
Organic[1] Sales Growth		+7%
Operating EBITDA	$2,512	+18%
Operating EBITDA Margin	30.8%	+343 bps

Seed Operating EBITDA ($ in millions)



2025 YTD Revenue by Product Line



Summary Takeaways

- Price/mix gains in most regions on demand for new technology, increased out-licensing income
- Higher corn volumes in North America[4] and Brazil, partially offset by lower soybean acres in the U.S.
- Cost benefit from productivity, lower commodity costs, partly offset by higher compensation, commissions, and R&D

(1) Organic sales growth is a non-GAAP measure. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) Other oilseeds includes sunflower and canola.
(3) Other product line primarily includes cotton, alfalfa, sorghum, wheat, rice, inoculants, and millet.
(4) North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa.

2025 YTD Regional Net Sales Highlights – Seed

Global Net Sales



Reported
5%

Organic[1]
7%

Volume	Price/Mix	Currency	Portfolio
4%	3%	(2)%	-%

North America[2]

Reported 6% | Organic[1] 6%

	2024 YTD	2025 YTD
Net Sales ($M)	$5,394	$5,726

Volume	Price/Mix	Currency	Portfolio
3%	3%	-%	-%

- Volume gains driven by increased corn acres and market share gains offsetting lower soybean acres
- Price/mix gains driven by demand for technology and increased out-licensing income

EMEA[2]

Reported Flat | Organic[1] 7%

	2024 YTD	2025 YTD
Net Sales ($M)	$1,365	$1,370

Volume	Price/Mix	Currency	Portfolio
2%	5%	(7)%	-%

- Price/mix gains driven by strong execution, demand for technology, and to offset currency
- Volume gains driven by strong demand for corn, despite acreage reductions due to drought in key markets

Latin America

Reported 5% | Organic[1] 11%

	2024 YTD	2025 YTD
Net Sales ($M)	$696	$730

Volume	Price/Mix	Currency	Portfolio
14%	(3)%	(6)%	-%

- Higher volume driven by increased corn area in Brazil and early safrinha deliveries, partially offset by JIT behavior in Argentina
- Price/mix declines driven by competitive corn technology alternatives in Argentina

Asia Pacific

Reported 5% | Organic[1] 7%

	2024 YTD	2025 YTD
Net Sales ($M)	$318	$335

Volume	Price/Mix	Currency	Portfolio
-%	7%	(2)%	-%

- Volume reflects corn market recovery in India and Pakistan, offset by delayed mustard season in India due to heavy rains
- Strong price/mix execution across the portfolio

CORTEVA agriscience

(1) Organic sales growth is a non-GAAP measure. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) North America is defined as U.S. and Canada. EMEA Is defined as Europe, Middle East and Africa.

3Q 2025 Crop Protection Performance Highlights

($ in millions)	3Q 2025	vPY
Net Sales	$1,701	+4%
Organic[1] Sales Growth		+3%
Operating EBITDA	$279	+13%
Operating EBITDA Margin	16.4%	+ 136 bps

Crop Protection Operating EBITDA ($ in millions)



3Q 2025 Revenue by Product Line



Summary Takeaways

- Volume gains in most regions, including double-digit volume growth in new products and biologicals
- Price gains in North America[3] more than offset by competitive market dynamics in Brazil
- Cost benefit from productivity gains

CORTEVA agriscience

(1) Organic sales growth is a non-GAAP measure. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) Other product line primarily includes seed applied technology.
(3) North America is defined as U.S. and Canada. EMEA Is defined as Europe, Middle East and Africa

3Q 2025 Regional Net Sales Highlights – Crop Protection

Global Net Sales



Reported ↑ 4%

Organic[1] ↑ 3%

Volume	Price/Mix	Currency	Portfolio
5%	(2)%	1%	-%

North America[2]

Reported ↑ 21% | Organic[1] ↑ 21%

	3Q 2024	3Q 2025
Net Sales ($M)	$440	$532

Volume	Price/Mix	Currency	Portfolio
18%	3%	-%	-%

- Higher volume driven by strong demand for herbicides and nitrogen stabilizers
- Price includes mid-season pricing adjustment

Latin America

Reported Flat | Organic[1] ↓ 2%

	3Q 2024	3Q 2025
Net Sales ($M)	$771	$770

Volume	Price/Mix	Currency	Portfolio
4%	(6)%	2%	-%

- Broad-based volume growth, led by double-digit growth in fungicides and biologicals
- Price reflects continued competitive market dynamics in Brazil and Argentina

EMEA[2]

Reported ↓ 9% | Organic[1] ↓ 15%

	3Q 2024	3Q 2025
Net Sales ($M)	$219	$200

Volume	Price/Mix	Currency	Portfolio
(11)%	(4)%	6%	-%

- Volume declines driven by early season demand shifting sales to 2Q, partially offset by ramp up of biologicals
- Currency tailwind driven by EUR

Asia Pacific

Reported ↓ 3% | Organic[1] Flat

	3Q 2024	3Q 2025
Net Sales ($M)	$205	$199

Volume	Price/Mix	Currency	Portfolio
2%	(2)%	(2)%	(1)%

- Volume gains led by Pyraxalt on increased rice acreage and higher pest pressure
- Price reflects market competitiveness

CORTEVA™ agriscience

(1) Organic sales growth is a non-GAAP measure. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) North America is defined as U.S. and Canada. EMEA Is defined as Europe, Middle East and Africa.

2025 YTD Crop Protection Performance Highlights

($ in millions)	2025 YTD	vPY
Net Sales	$5,330	+3%
Organic[1] Sales Growth		+5%
Operating EBITDA	$990	+22%
Operating EBITDA Margin	18.6%	+285 bps

Crop Protection Operating EBITDA ($ in millions)



2025 YTD Revenue by Product Line



Summary Takeaways

- Volume gains across the portfolio, including double-digit volume growth in fungicides, new products and biologicals
- Price reflects competitive market dynamics in Brazil
- Cost benefit from lower raw material costs and productivity gains, partially offset by higher bad debt and compensation

(1) Organic sales growth is a non-GAAP measure. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) Other product line primarily includes seed applied technology.

2025 YTD Regional Net Sales Highlights – Crop Protection

Global Net Sales



Reported ↑ 3%

Organic[1] ↑ 5%

Volume	Price/Mix	Currency	Portfolio
7%	(2)%	(2)%	-%

North America[2]

Reported ↑ 7% | Organic[1] ↑ 8%

	2024 YTD	2025 YTD
Net Sales ($M)	$1,703	$1,820

Volume	Price/Mix	Currency	Portfolio
8%	-%	(1)%	-%

- Higher volume driven by strong demand for herbicides, ramp of biologicals
- Price reflects competitive market dynamics in Canada, partially offset by mid-season price increase

Latin America

Reported ↑ 6% | Organic[1] ↑ 10%

	2024 YTD	2025 YTD
Net Sales ($M)	$1,458	$1,545

Volume	Price/Mix	Currency	Portfolio
17%	(7)%	(4)%	-%

- Broad-based double-digit volume growth, led by fungicides, driven by strength of portfolio
- Price reflects continued competitive market dynamics in Brazil and Argentina

EMEA[2]

Reported Flat | Organic[1] ↑ 1%

	2024 YTD	2025 YTD
Net Sales ($M)	$1,311	$1,316

Volume	Price/Mix	Currency	Portfolio
2%	(1)%	(1)%	- %

- Volume gains driven by demand for new products and growing fungicide portfolio
- Price pressure on off-patent portfolio

Asia Pacific

Reported ↓ 5% | Organic[1] ↓ 3%

	2024 YTD	2025 YTD
Net Sales ($M)	$685	$649

Volume	Price/Mix	Currency	Portfolio
(3)%	-%	(1)%	(1)%

- Volume reflects competitive market dynamics and adverse weather in key markets
- Price reflects market competitiveness

CORTEVA™ agriscience

(1) Organic sales growth is a non-GAAP measure. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) North America is defined as U.S. and Canada. EMEA Is defined as Europe, Middle East and Africa.

3Q 2025 Operating EPS[1] Variance



Volume/Price 1

- Mid-single digit Seed price/mix and volume gains in Seed and Crop Protection partially offset by competitive price pressure in Crop Protection

Costs 2

- Realization of Seed and Crop Protection raw material input cost deflation and ongoing productivity actions, partially offset by increased SARD

Currency 3

- Currency headwinds primarily from the Brazilian Real

Exchange Gain / Loss (EGL) 5

- Primarily reflects lower after-tax exchange losses related to the balance sheet hedge program

Portfolio / Other 6

- Reflects lower net interest expense and lower base tax rate

(1) Operating earnings per share and base income tax rate are non-GAAP measures. See slide 3 for further discussion.

FY 2025 Operating EBITDA[1]

FY 2025 Bridge



Key Drivers

- **LSD price/mix gains in Seed** to capture value for technology, partially offset by additional **Crop Protection market price pressure**
- **Volume gains** driven by Crop Protection **new products** and **biologicals** and additional **North America** and **Latin America corn acres** in Seed
- **~$90M improvement in Seed net royalties**, driven by increased out-licensing of Conkesta E3®[2] soybeans and PowerCore Enlist® corn
- **~$525M net cost of sales improvement** driven by lower Seed and Crop Protection input costs and productivity
- **SG&A and R&D spend as % of sales** up slightly versus 2024
- **~($200M)** currency headwind driven by BRL, TRY, and CAD
- Impact of tariffs **included** but **immaterial on a net basis** given ongoing mitigation actions

Margin Expansion Driven by Volume Gains and Cost Benefits

(1) Operating EBITDA and Operating EBITDA margin are non-GAAP measures. Corteva is not able to reconcile its forward-looking non-GAAP financial measures to their most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the company's control, such as Significant Items, without unreasonable effort. See slide 3 for further discussion and reconciliations at the end of this presentation.
(2) The transgenic event in the Conkesta E3® soybeans is jointly developed and owned by Corteva Agriscience and M.S. Technologies L.L.C.

FY 2025 Modeling Guidance – Operating Earnings Per Share[1]

($ in millions, except where noted)	Guidance
Depreciation and Post-Merge Amortization	(625 – 635)
Net Interest (Expense) Income	(75 – 85)
Base Income Tax Rate[1]	22% – 24%
Exchange Losses – net, after tax	(180 – 200)
Net Income – Non-controlling interest	(12)
Diluted Shares	681 – 683
Operating Earnings Per Share[1]	$3.25 – 3.35

($ in millions, except where noted)	Cash Flow Guidance
Amortization	~660
Capital Expenditures	~600

(1) Operating earnings per share and base income tax rate are non-GAAP measures. Corteva does not provide a reconciliation of forward-looking non-GAAP measures. See slide 3 for further discussion.

Separation Spotlight: Crop Protection Innovation and Market Conditions

CORTEVA™ agriscience

CP New Products Delivering Differentiated Solutions Across High-Value Market Opportunities Around the World

		Region	Peak NTR*[2] ($M)	Corn	Soybeans	Cereals	Fruit & Vegetables	Rice	Others
Weed Control	Arylex™ active	NA, LA, EMEA, AP	$$$		✓	✓			✓
	Enlist™ weed control system	NA, LA	$$	✓	✓				✓
	Rinskor™ active	NA, LA, EMEA, AP	$$$	✓	✓			✓	✓
	Bexoveld™ active[1]	NA, LA, EMEA, AP	$	✓		✓			✓
Disease Management	Inatreq™ active	LA, EMEA, AP	$			✓			✓
	Haviza™ active[1]	LA	$$		✓				
	Zorvec™ active	LA, EMEA, AP	$				✓		
	Adavelt™ active	NA, LA, EMEA, AP	$			✓	✓		✓
Insect / Nematode Management	Pyraxalt™ active	AP	$					✓	
	Reklemel™ active	NA, LA, EMEA, AP	$		✓		✓		✓
	Kinrayza™ active[1]	NA, LA, AP	$	✓	✓		✓	✓	✓
	Varpelgo™ active[1]	NA, LA, EMEA, AP	$$$	✓	✓	✓	✓	✓	✓

- **New Products** expected to cross $2B in annual sales in 2027, delivering **~$600M** in incremental top-line growth (2027E vs 2024A) at **~12%** average CAGR
- **Differentiation[3] mix** steady at **~65%** for 2025E, with margins **~10-15** percentage points higher than overall CP portfolio
- The largest molecule concentration in the CP portfolio (**Spinosyn** portfolio), represents **~11%** of total CP revenues
- Arylex™ and Rinskor™ combined revenues approaching **$1B by 2027**

***Peak Net Trade Revenue (NTR) Categories:**
$$$ = >$750M
$$ = $500M – $750M
$ = ~$200M - $500M

CORTEVA agriscience

[1] Pending applicable regulatory approvals.
[2] Represents the sum of all peak revenue (regardless of the peak year) from all actives before cannibalization through 2038.
[3] Differentiated products include (1) active ingredients and biological products patented in major markets, (2) highly differentiated actives not encountering generic competition due to trade-secrets, manufacturing or technical barriers to entry and (3) products (inclusive of biologicals) providing market leading performance attributes that are protected by trade-secret or unique formulation patents.

Market-Leading $9 Billion Crop Protection Pipeline

Herbicides / Weed Control

- #1 globally in non-glyphosate herbicides (#1 in US and Brazil)
- ~$1.5B of 2027E sales for Enlist™, Arylex™, and Rinskor™
- Expanding technology application to new markets
- New MOA herbicide to launch in mid-2030's

Insecticides and Nematode Management

- ~$1B peak revenue incremental to Spinosyns franchise
- Kinrayza™ and Varpelgo™ advancing in pipeline
- Reklemel™ aimed at $80B of annual nematode damage

Fungicides / Disease Management

- Billion-dollar fungicides deliver broad disease control
- ~$1B peak revenue from three generations of naturally-derived picolinamides
- Ramping up Inatreq™, expanding global registrations for Adavelt™
- Haviza™ launching in Brazil in 2026 to combat Asian Soybean Rust



Biologicals

- Expecting $1B of biologicals revenue by end of decade
- Projecting double-digit revenue CAGR's across all regions 2025-2027
- Led by Utrisha®N penetration with strong value proposition

Seed Applied Technologies

- Expanding portfolio through internal innovation with Varpelgo™ active insecticide, Biologicals, and external collaboration
- Expanding business with other seed players, through multiple routes-to-market

Pipeline Value reflects Substantive Growth Opportunities across Portfolio

[1] Represents the sum of all peak revenue (regardless of the peak year) from all actives before cannibalization through 2038.

2026 Crop Protection Market Assumptions

2026 Crop Protection Total Market Outlook ($B)



2025E Crop Protection Sales by Indication



Low-Single-Digit Market Growth in 2026 Aligns with 2027 Framework Assumptions

Source: Corteva Internal Analysis

Stay tuned next quarter, when we will feature…

Separation Spotlight: Advanced Genetics Innovation

CORTEVA™ agriscience

Preview: $1 Billion+[1] Market Opportunity in North America Corn

Multi-Disease Resistance (MDR) Corn

- Gene editing-enabled product with resistance to three key corn diseases for initial launch[2]
- Broad spectrum "in the seed" control helps growers manage year-to-year disease fluctuations
- Design simplicity allows introduction across hybrids and market segments
- Yield protection under even extremely high disease pressure

NA launch[3] in 2028

Trait Performance Under Heavy Southern Corn Rust (SCR)

NLB testing trials were overwhelmed with extreme natural SCR pressure. MDR-containing plants outyielded controls on average by 50bu/ac[4]



RBG Imagery Field Trials

NDVI Imagery Field Trials



August 26, 2025

[1] $595M for Grey Leaf Spot, $210M for Anthracnose Stalk Rot, $221M for Southern Rust, $212M for Northern Leaf Blight | Source: CPN Report for US & CA market, years 2017-2023.
[2] Three key diseases for initial launch: Northern Leaf Blight, Southern Rust, and Gray Leaf Spot (Anthracnose Stalk Rot planned for future inclusion)
[3] Launch pending applicable global regulatory reviews and completion of field testing
[4] Replicated field trials done without fungicide application in Johnston, IA 2025

Product Disclosures

TM ® SM Trademarks and service marks of Corteva Agriscience and its affiliated companies. © 2025 Corteva and its affiliated companies.

The transgenic soybean event in Enlist E3® soybeans is jointly developed and owned by Corteva Agriscience LLC and M.S. Technologies, L.L.C. Enlist Duo® and Enlist One® herbicides are not registered for sale or use in all states or counties. Contact your state pesticide regulatory agency to determine if a product is registered for sale or use in your area. Enlist Duo and Enlist One are the only 2,4-D products authorized for use with Enlist crops. Consult Enlist herbicide labels for weed species controlled. Always read and follow label directions.

Qrome® products are approved for cultivation in the U.S. and Canada. They have also received approval in a number of importing countries, most recently China. For additional information about the status of regulatory authorizations, visit http://www.biotradestatus.com/

Pioneer® brand products are provided subject to the terms and conditions of purchase which are part of the labeling and purchase document.

Thank you

CORTEVA™
agriscience

Corteva, Inc.
Non-GAAP Calculation of Corteva Operating EBITDA

	Three Months Ended September 30,				Nine Months Ended September 30,			
	2025		2024		2025		2024	
$ In millions	*As Reported*	Margin %	*As Reported*	Margin %	*As Reported*	Margin %	*As Reported*	Margin %
Income (loss) from continuing operations after income taxes (GAAP)	$ (308)	(11.8)%	$ (519)	(22.3)%	$ 1,741	12.9 %	$ 913	7.1 %
Provision for (benefit from) income taxes on continuing operations	(62)	(2.4)%	(114)	(4.9)%	477	3.5 %	274	2.1 %
Income (loss) from continuing operations before income taxes (GAAP)	$ (370)	(14.1)%	$ (633)	(27.2)%	$ 2,218	16.4 %	$ 1,187	9.2 %
+ Depreciation and amortization	300	11.5 %	306	13.2 %	897	6.6 %	925	7.2 %
- Interest income	(29)	(1.1)%	(33)	(1.4)%	(92)	(0.7)%	(93)	(0.7)%
+ Interest expense	46	1.8 %	66	2.8 %	134	1.0 %	173	1.3 %
+ / - Exchange (gains) losses - net	45	1.7 %	97	4.2 %	97	0.7 %	234	1.8 %
+ / - Non-operating (benefits) costs - net	14	0.5 %	50	2.1 %	27	0.2 %	132	1.0 %
+ / - Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	6	0.2 %	14	0.6 %	58	0.4 %	(4)	— %
+ / - Significant items (benefit) charge	30	1.1 %	33	1.4 %	56	0.4 %	297	2.3 %
+ Separation costs	7	0.3 %	—	— %	7	0.1 %	—	— %
Corteva Operating EBITDA / EBITDA Margin (Non-GAAP) [1,2]	$ 49	1.9 %	$ (100)	(4.3)%	$ 3,402	25.2 %	$ 2,851	22.0 %

1. Corteva Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.

2. The EBITDA margin percentages are determined by dividing amounts in the table above for the three months ended September 30, 2025 and 2024 by net sales of $2,618 million and $2,326 million, respectively, and amounts for the nine months ended September 30, 2025 and 2024 by net sales of $13,491 million and $12,930 million, respectively. Margin percentages may not foot, due to rounding.

Corteva, Inc.
Segment Information

Net sales by segment

In millions	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2025	Nine Months Ended September 30, 2024
Seed	$ 917	$ 691	$ 8,161	$ 7,773
Crop Protection	1,701	1,635	5,330	5,157
Total net sales	$ 2,618	$ 2,326	$ 13,491	$ 12,930

Net Margin (GAAP)

$ In millions	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2025	Nine Months Ended September 30, 2024
Income (loss) from continuing operations after income taxes	$ (308)	$ (519)	$ 1,741	$ 913
Net Margin GAAP [1]	(11.8)%	(22.3)%	12.9 %	7.1 %

1. Net Margin is defined as income (loss) from continuing operations after income taxes, as a percentage of net sales.

Corteva Operating EBITDA

In millions	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2025	Nine Months Ended September 30, 2024
Seed	$ (193)	$ (320)	$ 2,512	$ 2,126
Crop Protection	279	246	990	811
Corporate Expenses	(37)	(26)	(100)	(86)
Corteva Operating EBITDA (Non-GAAP) [2]	$ 49	$ (100)	$ 3,402	$ 2,851

2. Corteva Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.

Operating EBITDA Margin

	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2025	Nine Months Ended September 30, 2024
Seed	(21.0)%	(46.3)%	30.8 %	27.4 %
Crop Protection	16.4 %	15.0 %	18.6 %	15.7 %
Total Operating EBITDA Margin (Non-GAAP) [3,4]	1.9 %	(4.3)%	25.2 %	22.0 %

3. Operating EBITDA margin is Operating EBITDA as a percentage of net sales.

4. Operating EBITDA margin %s for Corporate are not presented separately above as they are not meaningful; however, the results are included in the Total margin %s above.

Corteva, Inc.
Segment Information

Corteva significant items (Pre-tax)

In millions	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2025	Nine Months Ended September 30, 2024
Seed				
Restructuring and asset related charges - net	$ —	$ (3)	$ (4)	$ (56)
Inventory write-offs	—	—	—	2
Gain (loss) on sale of assets	—	—	—	4
AltEn facility remediation charges	—	—	(37)	—
Total Seed	$ —	$ (3)	$ (41)	$ (50)
Crop Protection				
Restructuring and asset related charges - net	$ (28)	$ (10)	$ (117)	$ (83)
Estimated settlement expense	—	—	—	(101)
Gain (loss) on sale of assets	—	—	14	3
Acquisition-related costs	—	(1)	—	(6)
Insurance proceeds	—	—	98	—
Total Crop Protection	$ (28)	$ (11)	$ (5)	$ (187)
Corporate				
Restructuring and asset-related charges - net	$ (2)	$ (19)	$ (10)	$ (60)
Total Corporate	$ (2)	$ (19)	$ (10)	$ (60)
Total pre-tax significant items benefit (charge) by segment	$ (30)	$ (33)	$ (56)	$ (297)
Total tax (provision) benefit impact of significant items [1]	7	8	15	74
Tax only significant item benefit (charge)	—	4	55	4
Total significant items benefit (charge), after tax [2]	$ (23)	$ (21)	$ 14	$ (219)

1. Unless specifically addressed above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

2. Refer to page A-10 of the Financial Statement Schedules for further information on significant items.

Corteva, Inc.
Segment Information - Price, Volume, Currency Analysis

Region

	Q3 2025 vs. Q3 2024				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change (Non-GAAP) [2]		Price & Product Mix	Volume	Currency	Portfolio / Other
	$ (millions)	*%*	*$ (millions)*	*%*				
North America [1]	$ 97	16 %	$ 99	16 %	6 %	10 %	— %	— %
EMEA [1]	47	11 %	29	7 %	1 %	6 %	4 %	— %
Latin America	172	17 %	150	15 %	(5)%	20 %	2 %	— %
Asia Pacific	(24)	(8)%	(17)	(5)%	1 %	(6)%	(2)%	(1)%
Rest of World	195	11 %	162	9 %	(3)%	12 %	2 %	— %
Total	$ 292	13 %	$ 261	11 %	(1)%	12 %	2 %	— %

Seed

	Q3 2025 vs. Q3 2024				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change (Non-GAAP) [2]		Price & Product Mix	Volume	Currency	Portfolio / Other
	$ (millions)	*%*	*$ (millions)*	*%*				
North America [1]	$ 5	3 %	$ 6	4 %	12 %	(8)%	(1)%	— %
EMEA [1]	66	34 %	61	31 %	5 %	26 %	3 %	— %
Latin America	173	79 %	165	76 %	(2)%	78 %	3 %	— %
Asia Pacific	(18)	(17)%	(17)	(16)%	4 %	(20)%	(1)%	— %
Rest of World	221	42 %	209	40 %	2 %	38 %	2 %	— %
Total	$ 226	33 %	$ 215	31 %	4 %	27 %	2 %	— %

Crop Protection

	Q3 2025 vs. Q3 2024				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change (Non-GAAP) [2]		Price & Product Mix	Volume	Currency	Portfolio / Other
	$ (millions)	*%*	*$ (millions)*	*%*				
North America [1]	$ 92	21 %	$ 93	21 %	3 %	18 %	— %	— %
EMEA [1]	(19)	(9)%	(32)	(15)%	(4)%	(11)%	6 %	— %
Latin America	(1)	— %	(15)	(2)%	(6)%	4 %	2 %	— %
Asia Pacific	(6)	(3)%	—	— %	(2)%	2 %	(2)%	(1)%
Rest of World	(26)	(2)%	(47)	(4)%	(5)%	1 %	2 %	— %
Total	$ 66	4 %	$ 46	3 %	(2)%	5 %	1 %	— %

1. North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa.

2. Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items.

Corteva, Inc.
Segment Information - Price, Volume, Currency Analysis

Seed Product Line

	Q3 2025 vs. Q3 2024				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change (Non-GAAP) [1]		Price & Product Mix	Volume	Currency	Portfolio / Other
	$ (millions)	*%*	*$ (millions)*	*%*				
Corn	$ 271	86 %	$ 263	83 %	7 %	76 %	3 %	— %
Soybeans	(12)	(7)%	(15)	(9)%	4 %	(13)%	2 %	— %
Other oilseeds	6	4 %	5	4 %	3 %	1 %	— %	— %
Other	(39)	(51)%	(38)	(49)%	(1)%	(48)%	(2)%	— %
Total	$ 226	33 %	$ 215	31 %	4 %	27 %	2 %	— %

Crop Protection Product Line

	Q3 2025 vs. Q3 2024				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change (Non-GAAP) [1]		Price & Product Mix	Volume	Currency	Portfolio / Other
	$ (millions)	*%*	*$ (millions)*	*%*				
Herbicides	$ 77	10 %	$ 64	9 %	(1)%	10 %	1 %	— %
Insecticides	(28)	(6)%	(32)	(7)%	(5)%	(2)%	1 %	— %
Fungicides	6	3 %	5	2 %	— %	2 %	2 %	(1)%
Biologicals	12	9 %	11	8 %	(4)%	12 %	1 %	— %
Other	(1)	(1)%	(2)	(2)%	(7)%	5 %	1 %	— %
Total	$ 66	4 %	$ 46	3 %	(2)%	5 %	1 %	— %

1. Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items.

Corteva, Inc.
Segment Information - Price, Volume, Currency Analysis

Region

	Nine Months 2025 vs. Nine Months 2024				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change (Non-GAAP) [2]		Price & Product Mix	Volume	Currency	Portfolio / Other
	$ (millions)	*%*	*$ (millions)*	*%*				
North America [1]	$ 449	6 %	$ 477	7 %	2 %	5 %	(1)%	— %
EMEA [1]	10	— %	108	4 %	2 %	2 %	(4)%	— %
Latin America	121	6 %	218	10 %	(6)%	16 %	(4)%	— %
Asia Pacific	(19)	(2)%	1	— %	2 %	(2)%	(2)%	— %
Rest of World	112	2 %	327	6 %	— %	6 %	(4)%	— %
Total	$ 561	4 %	$ 804	6 %	1 %	5 %	(2)%	— %

Seed

	Nine Months 2025 vs. Nine Months 2024				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change (Non-GAAP) [2]		Price & Product Mix	Volume	Currency	Portfolio / Other
	$ (millions)	*%*	*$ (millions)*	*%*				
North America [1]	$ 332	6 %	$ 349	6 %	3 %	3 %	— %	— %
EMEA [1]	5	— %	92	7 %	5 %	2 %	(7)%	— %
Latin America	34	5 %	74	11 %	(3)%	14 %	(6)%	— %
Asia Pacific	17	5 %	23	7 %	7 %	— %	(2)%	— %
Rest of World	56	2 %	189	8 %	3 %	5 %	(6)%	— %
Total	$ 388	5 %	$ 538	7 %	3 %	4 %	(2)%	— %

Crop Protection

	Nine Months 2025 vs. Nine Months 2024				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change (Non-GAAP) [2]		Price & Product Mix	Volume	Currency	Portfolio / Other
	$ (millions)	*%*	*$ (millions)*	*%*				
North America [1]	$ 117	7 %	$ 128	8 %	— %	8 %	(1)%	— %
EMEA [1]	5	— %	16	1 %	(1)%	2 %	(1)%	— %
Latin America	87	6 %	144	10 %	(7)%	17 %	(4)%	— %
Asia Pacific	(36)	(5)%	(22)	(3)%	— %	(3)%	(1)%	(1)%
Rest of World	56	2 %	138	4 %	(3)%	7 %	(2)%	— %
Total	$ 173	3 %	$ 266	5 %	(2)%	7 %	(2)%	— %

1. North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa.

2. Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items.

Corteva, Inc.
Segment Information - Price, Volume, Currency Analysis

Seed Product Line

	Nine Months 2025 vs. Nine Months 2024				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change (Non-GAAP) [1]		Price & Product Mix	Volume	Currency	Portfolio / Other
	$ (millions)	*%*	*$ (millions)*	*%*				
Corn	$ 531	10 %	$ 649	13 %	4 %	9 %	(3)%	— %
Soybeans	(59)	(3)%	(57)	(3)%	1 %	(4)%	— %	— %
Other oilseeds	(16)	(3)%	6	1 %	3 %	(2)%	(4)%	— %
Other	(68)	(19)%	(60)	(17)%	4 %	(21)%	(2)%	— %
Total	$ 388	5 %	$ 538	7 %	3 %	4 %	(2)%	— %

Crop Protection Product Line

	Nine Months 2025 vs. Nine Months 2024				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change (Non-GAAP) [1]		Price & Product Mix	Volume	Currency	Portfolio / Other
	$ (millions)	*%*	*$ (millions)*	*%*				
Herbicides	$ 100	4 %	$ 134	5 %	(2)%	7 %	(1)%	— %
Insecticides	(44)	(4)%	(20)	(2)%	(3)%	1 %	(2)%	— %
Fungicides	107	14 %	133	17 %	(1)%	18 %	(3)%	— %
Biologicals	21	7 %	31	10 %	(5)%	15 %	(3)%	— %
Other	(11)	(4)%	(12)	(4)%	(3)%	(1)%	— %	— %
Total	$ 173	3 %	$ 266	5 %	(2)%	7 %	(2)%	— %

1. Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items.

Corteva, Inc.
Non-GAAP Calculation of Corteva Operating EPS

	Three Months Ended September 30,			
	2025	2024	2025	2024
	$ (millions)	$ (millions)	EPS (diluted)	EPS (diluted)
Income (loss) from continuing operations attributable to Corteva common stockholders (GAAP)	$ (310)	$ (522)	$ (0.46)	$ (0.76)
Less: Non-operating benefits (costs), after tax [1]	(12)	(37)	(0.02)	(0.05)
Less: Amortization of intangibles (existing as of Corteva Separation), after tax	(108)	(115)	(0.16)	(0.17)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax	(4)	(11)	(0.01)	(0.02)
Less: Significant items benefit (charge), after tax	(23)	(21)	(0.03)	(0.03)
Less: Separation costs, after tax	(7)	—	(0.01)	—
Operating Earnings (Loss) (Non-GAAP) [2]	$ (156)	$ (338)	$ (0.23)	$ (0.49)

	Nine Months Ended September 30,			
	2025	2024	2025	2024
	$ (millions)	$ (millions)	EPS (diluted)	EPS (diluted)
Income (loss) from continuing operations attributable to Corteva common stockholders (GAAP)	$ 1,733	$ 903	$ 2.54	$ 1.29
Less: Non-operating benefits (costs), after tax [1]	(28)	(98)	(0.04)	(0.14)
Less: Amortization of intangibles (existing as of Corteva Separation), after tax	(327)	(350)	(0.48)	(0.50)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax	(44)	3	(0.06)	—
Less: Significant items benefit (charge), after tax	14	(219)	0.02	(0.31)
Less: Separation costs, after tax	(7)	—	(0.01)	—
Operating Earnings (Loss) (Non-GAAP) [2]	$ 2,125	$ 1,567	$ 3.11	$ 2.24

1. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.

2. Operating earnings (loss) is defined as income (loss) from continuing operations attributable to Corteva excluding the after-tax impact of significant items, the after-tax impact of separation costs, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Corteva Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of intangible assets (existing as of Corteva Separation) is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

Corteva, Inc.
Non-GAAP Calculation of Corteva Base Income Tax Rate

$ In millions	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2025	Nine Months Ended September 30, 2024
Income (loss) from continuing operations before income taxes (GAAP)	$ (370)	$ (633)	$ 2,218	$ 1,187
Add: Significant items (benefit) charge	30	33	56	297
Separation costs	7	—	7	—
Non-operating (benefits) costs	14	50	27	132
Amortization of intangibles (existing as of Corteva Separation)	142	151	427	459
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	6	14	58	(4)
Less: Exchange gains (losses) [1]	(45)	(97)	(97)	(234)
Income (loss) from continuing operations before income taxes, significant items, separation costs, non-operating (benefits) costs, amortization of intangibles (existing as of Corteva Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange gains (losses) (Non-GAAP)	$ (126)	$ (288)	$ 2,890	$ 2,305
Provision for (benefit from) income taxes on continuing operations (GAAP)	$ (62)	$ (114)	$ 477	$ 274
Add: Tax (expenses) benefits on significant items (benefit) charge	7	12	70	78
Tax benefits on separation costs	—	—	—	—
Tax (expenses) benefits on non-operating (benefits) costs	2	13	(1)	34
Tax benefits on amortization of intangibles (existing as of Corteva Separation)	34	36	100	109
Tax (expenses) benefits on mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	2	3	14	(1)
Tax (expenses) benefits on exchange gains (losses) [1]	(5)	(7)	(19)	30
Provision for (benefit from) income taxes on continuing operations before significant items, separation costs, non-operating (benefits) costs, amortization of intangibles (existing as of Corteva Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange gains (losses) (Non-GAAP)	$ (22)	$ (57)	$ 641	$ 524
Effective income tax rate (GAAP)	16.8 %	18.0 %	21.5 %	23.1 %
Significant items, separation costs, non-operating (benefits) costs, amortization of intangibles (existing as of Corteva Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect	(6.8)%	(5.0)%	2.1 %	0.8 %
Tax rate from continuing operations before significant items, separation costs, non-operating (benefits) costs, amortization of intangibles (existing as of Corteva Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	10.0 %	13.0 %	23.6 %	23.9 %
Exchange gains (losses), net effect [1]	7.5 %	6.8 %	(1.4)%	(1.2)%
Base income tax rate from continuing operations (Non-GAAP) [2]	17.5 %	19.8 %	22.2 %	22.7 %

1. Refer to page A-15 of the Financial Statement Schedules for further information on exchange gains (losses).

2. Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), significant items, separation costs, amortization of intangibles (existing as of Corteva Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and non-operating (benefits) costs.

Corteva, Inc.
Non-GAAP Calculation of Free Cash Flow

In millions	Twelve Months Ended December 31, 2025[2]	
	Low End	**High End**
Cash provided by (used for) operating activities - continuing operations (GAAP)	$ 2,475	$ 2,525
Less: Capital expenditures	(600)	(600)
Free Cash Flow (Non-GAAP) [1]	$ 1,875	$ 1,925

1. Free Cash Flow is defined as cash provided by (used for) operating activities - continuing operations, less capital expenditures.

2. This represents the reconciliation of the Company's range provided for its forward-looking non-GAAP financial measures relating to Free Cash Flow.

Corteva is not able to reconcile its forward-looking Free Cash Flow Conversion non-GAAP financial measure to its most comparable U.S. GAAP financial measure, as it is unable to predict with reasonable certainty Operating EBITDA due to items outside of the Company's control, which include Significant Items, without unreasonable effort.